English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 16 April 2020, 16:57 HKT/SGT
Share:
MicroPort CardioFlow Completes Raising New Round of Funds

SHANGHAI, CHINA, Apr 16, 2020 - (ACN Newswire) - On April 15, 2020, MicroPort Scientific Corporation (Stock code: 00853) ("MicroPort"), announced that MicroPort CardioFlow Medtech Corporation ("MicroPort CardioFlow"), which is a subsidiary of MicroPort, had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction of seven prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million. After this round of fundraising, the investors will have an aggregate shareholding of 10.83% in MicroPort CardioFlow. J.P. Morgan Securities (Asia Pacific) Limited and Citigroup Global Markets Asia Limited acted as co-placement agents in the transaction.

MicroPort CardioFlow focuses on the research, development, manufacturing and marketing of comprehensive medical device solutions to the treatment of valvular heart diseases. Its independently developed VitaFlow Transcatheter Aortic Valve and Delivery System ("VitaFlow Valve System") received the registration certificate from National Medical Products Administration of China (NMPA) in July 2019. VitaFlow Valve System is the first approved Transcatheter Aortic Valve Implantation (TAVI) product using bovine pericardium as valve tissue in China, as well as the first TAVI product that features a double-layer PET skirt and a motorized delivery system in China. Accompanied by Alwide Balloon Dilation Catheter and Alpass Catheter Sheath Set, which were independently developed by MicroPort CardioFlow and approved by NMPA, VitaFlow Valve System provides a comprehensive full-set therapeutic solution for clinicians. The clinical data of VitaFlow Valve System have proved that the product can effectively improve the safety and efficacy of the TAVI procedure, which has been widely endorsed by industry experts and clinicians in practice. VitaFlow Valve System launched its official commercialization in August 2019. As of April 16, 2020, the products have entered a total of 51 hospitals with TAVI capacity, including Zhongshan Hospital Affiliated to Fudan University, Chinese Academy of Medical Sciences Fuwai Hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine, and Wuhan Asia Heart Hospital.

Dr. Qiyi Luo, Chief Technology Officer of MicroPort and Chairman of MicroPort CardioFlow, said, "With about 10 years of committed development of its aortic valve business, MicroPort CardioFlow has become an influential player in the field of heart valve in China and been favored by the capital market. This round of fundraising will bring in more resources for the development of the company in research and development, manufacturing, market expansion, and the enhancement of its market competitiveness. We have every confidence that we will maintain rapid development in the niche market of medical devices for valvular heart diseases, so as to provide more patients with high-quality and accessible integrated therapeutic solutions to valvular diseases."



Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
CWE held 'Lancang Mekong Green Course' Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station  
July 28, 2025 14:10 HKT/SGT
From Hong Kong Airport to Hengqin: Chimelong Ferry Sets Sail for a Worry-Free Journey  
July 28, 2025 13:30 HKT/SGT
Intelligent Tech Unlocks the Future - Connecting the World, CITIC Telecom Unveils Future-ready Solutions at WAIC 2025  
July 28, 2025 12:03 HKT/SGT
Phoenitron Grants Share Options and Sets HK$75 Million Profit Target for First Three Quarters  
July 28, 2025 11:28 HKT/SGT
OMS Energy Recorded Significant Profits Growth in 2025FY, Roth Capital Rating it "Buy" with a Potential 40% Upside TP  
July 27, 2025 23:00 HKT/SGT
Saudi Electricity Company Achieves 30% Increase in 2025 Sustainability Rating Compared to 2024, According to S&P  
July 27, 2025 22:45 HKT/SGT
Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making  
July 26, 2025 08:00 HKT/SGT
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming  
July 25, 2025 19:00 HKT/SGT
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics  
Friday, July 25, 2025 3:00:00 PM
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment  
Friday, July 25, 2025 12:31:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575